Please select a Capability in order to start your service request.
BD Signs Agreement with Island Health to Install Microbiology Platform by Fourth Quarter 2014May 20, 2014
MISSISSAUGA, ONTARIO, May 20, 2014 – BD (Becton, Dickinson and Company), a leading global medical technology company, today announced an agreement with Island Health to install the BD Kiestra™ Total Lab Automation (TLA) system. This fully-automated microbiology system will be installed at the Island Health’s Royal Jubilee Hospital site by the 4th quarter of calendar year 2014 making Island Health the first Regional Health Authority in Canada to implement the system. The BD Kiestra TLA system is designed to streamline the entire microbiology testing process and shorten the time to results, enabling clinicians faster access to diagnostic information.
“We look forward to working with BD as we install our BD Kiestra TLA system. This technology will help us live our Vision of Excellent care for everyone, everywhere, every time,” said Dr. Gordon Hoag, Medical Director, Laboratory Medicine at Island Health. “The implementation of this system will allow Island Health to support our capacity, improve result turnaround times, standardize processes, provide digitalized databases, enhance data retrieval and provide opportunities for optimal patient outcomes.”
The BD Kiestra TLA system automates the manual processes associated with inoculating and incubating microbiology specimens. The system generates digital images to help shorten the time to identify bacterial growth. The opportunities for increased efficiency and quality improvements associated with automation aid in faster delivery of more accurate results to provide optimal patient care. In addition, laboratory staff is able to devote more time to analytical and value-added tasks.
“BD is proud to be working with Island Health to increase diagnostic efficiencies while delivering better patient outcomes and care,” said Lawrence Mahan, Business Director, BD Diagnostics - Diagnostic Systems, BD in Canada. “By implementing the BD Kiestra TLA system, integrated with other rapid diagnostic technologies, Island Health is at the forefront of enabling the fastest possible identification and appropriate treatment of infectious disease.”
BD has installed a base of BD Kiestra TLA instruments at public hospitals, universities, and privately owned laboratories in more than 14 countries worldwide since their introduction in 2006. The BD Kiestra TLA system was launched in North America in 2013.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.